Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein ...
Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores ...
Alan Alda says the first Parkinson’s symptom that he experienced ‘was not that well-known’ at the time, adding that he had ...
OK Magazine on MSN
Alan Alda says he has to 'accept' living with Parkinson's disease: 'I can't wish it away'
Alan Alda opened up about his Parkinson's disease — 11 years after he was first diagnosed.
A human-specific GLUD2 gene variant worsens Parkinson's disease pathology in mice by driving complement C3 signaling from astrocytes to microglia, revealing a potential therapeutic target.
Alan Alda has lived publicly with Parkinson’s disease for eight years, but at 90 he still refuses to let the diagnosis become ...
Alan Alda opens up about Parkinson’s disease in a new interview, sharing, ‘It’s not who I am.’ ...
Tavapadon, a treatment for Parkinson’s disease recently approved by the FDA, provides a novel option for healthcare providers ...
Another potential blockbuster just joined AbbVie's drug portfolio.
Vima Therapeutics, a clinical-stage biotechnology company focused on oral therapies for movement disorders, today announced that four poster presentations will be featured at the 2026 International ...
Parkinson’s disease is a brain disorder that gradually affects movement and many other body functions. It develops as nerve ...
Researchers engineered a lipid nano-emulsion from solid myristic acid and liquid palm oil that encapsulates L-DOPA in sub-100-nanometer particles and releases the drug slowly across stomach and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results